SOPH
SellHot AirSOPHiA GENETICS SA · Healthcare · Switzerland · $693M · Avg Vol: $5M/d
Hot Air: Rising on momentum alone: weak business, rich price.
ABOUT SOPHIA GENETICS SA
Read
SOPHiA GENETICS is a Swiss-based technology company providing a data-driven medicine platform for healthcare institutions globally, with its AI-powered SOPHiA DDM™ analyzing genomic and radiomic data for clinical decision-making. The company's competitive advantage stems from its proprietary AI and machine learning algorithms, which aggregate and interpret large-scale genomic data from a vast network of partner institutions. This data-sharing ecosystem and advanced analytical capabilities position SOPHiA GENETICS as a leader in precision medicine informatics.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 47.6M | 62.4M | 65.2M | 77.3M | 17.6% | 86.2M | 95.2M | 118.7M | 23.9% |
| EPS | -1.36 | -1.22 | -0.95 | -1.17 | — | -1.16 | -0.85 | -0.50 | — |
| Shares | 64.2M | 65.2M | 66.7M | 68.5M | +6.6% | 85.1M | — | — | — |
| Debt | 16.7M | 18.6M | 30.0M | 63.0M | 55.6% | 61.8M | — | — | — |
| Equity | 200.1M | 151.4M | 96.5M | 47.1M | -38.2% | — | — | — | — |
| Op CF | -70.1M | -53.2M | -44.5M | -35.9M | — | -39.7M | — | — | — |
| Inv CF | 42.0M | 13.0M | -4.8M | -8.7M | — | — | — | — | — |
| Fin CF | -1.6M | -2.8M | 9.9M | 30.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of SOPH are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| SOPH | SOPHiA GENETICS SA(you) | $693M | 33 | Sell |
| ASCN.SW | Ascom Holding AG | $222M | 99 | Strong Buy |
| KURN.SW | Kuros Biosciences AG | $1.0B | 33 | Sell |
| AEVS.SW | Aevis Victoria SA | $1.4B | 34 | Sell |
| MED.SW | Medartis Holding AG | $1.4B | 39 | Hold |
| METN.SW | Metall Zug AG | $483M | 49 | Hold |
| OCS | Oculis Holding AG | $678M | 6 | Strong Sell |
| IDIA.SW | Idorsia Ltd | $1.7B | 22 | Sell |
| NVCR | NovoCure Limited | $2.1B | 40 | Hold |
| SANN.SW | Santhera Pharmaceuticals Holding AG | $290M | 20 | Sell |
Peer medians: ROE 11.1% · P/E 29.9x · Gross margin 58.7%
Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.